Assessment of Age-Induced Changes in Body Fat Percentage and BMI Aided by Bayesian Modelling: A Cross-Sectional Cohort Study in Middle-Aged and Older Adults.


Journal

Clinical interventions in aging
ISSN: 1178-1998
Titre abrégé: Clin Interv Aging
Pays: New Zealand
ID NLM: 101273480

Informations de publication

Date de publication:
2020
Historique:
received: 19 08 2020
accepted: 10 11 2020
entrez: 18 12 2020
pubmed: 19 12 2020
medline: 22 4 2021
Statut: epublish

Résumé

Loss of fat-free mass (FFM) and gain in body fat (BF) are the key disability risk factors, also instrumental in perpetuating already existing functional disorders. Obesity construed in terms of body mass index (BMI) values, in view of undesirable gain in BF, is a risk factor for cardio-metabolic disorders. Both detrimental processes clearly evidence a scope of involutionary changes characteristic of an aging population, also standing for one of its greatest burdens. The present study aimed to assess the changes in body composition (BC), in conjunction with the relationship between BF% and BMI, for defining overweight and obesity status in middle-aged and older adults, against the select indicator variables under study. The study involved 4799 individuals (33.7% men), PONS Project participants, aged 43-64 years. BF% was measured with the aid of bioelectrical impedance analysis (BIA) method. Age-induced changes in BC were determined against BF%, fat mass (FM), FFM, BMI, fat mass index (FMI), and fat-free mass index (FFMI). The relationship between BF% and BMI was established with the aid of Bayesian regression models, adjusted for gender and age. In both genders, BF% increased with age at a similar annual rate. The reduction of FFM was noted mainly in men, which in conjunction with BF% gain ensured BMI stability. The increase in BF% in women with stable FFM affected an increase in BMI. Regardless of the BMI threshold, the anticipated (predicted) BF% increased with age in both genders. Monitoring of BC is of particular importance in older adults, in view of appreciably better characteristics of both the short- and long-term health predictors, as well as overall potential for developing specifically targeted, effective health interventions.

Sections du résumé

BACKGROUND BACKGROUND
Loss of fat-free mass (FFM) and gain in body fat (BF) are the key disability risk factors, also instrumental in perpetuating already existing functional disorders. Obesity construed in terms of body mass index (BMI) values, in view of undesirable gain in BF, is a risk factor for cardio-metabolic disorders. Both detrimental processes clearly evidence a scope of involutionary changes characteristic of an aging population, also standing for one of its greatest burdens.
PURPOSE OBJECTIVE
The present study aimed to assess the changes in body composition (BC), in conjunction with the relationship between BF% and BMI, for defining overweight and obesity status in middle-aged and older adults, against the select indicator variables under study.
MATERIALS AND METHODS METHODS
The study involved 4799 individuals (33.7% men), PONS Project participants, aged 43-64 years. BF% was measured with the aid of bioelectrical impedance analysis (BIA) method. Age-induced changes in BC were determined against BF%, fat mass (FM), FFM, BMI, fat mass index (FMI), and fat-free mass index (FFMI). The relationship between BF% and BMI was established with the aid of Bayesian regression models, adjusted for gender and age.
RESULTS RESULTS
In both genders, BF% increased with age at a similar annual rate. The reduction of FFM was noted mainly in men, which in conjunction with BF% gain ensured BMI stability. The increase in BF% in women with stable FFM affected an increase in BMI. Regardless of the BMI threshold, the anticipated (predicted) BF% increased with age in both genders.
CONCLUSION CONCLUSIONS
Monitoring of BC is of particular importance in older adults, in view of appreciably better characteristics of both the short- and long-term health predictors, as well as overall potential for developing specifically targeted, effective health interventions.

Identifiants

pubmed: 33335389
doi: 10.2147/CIA.S277171
pii: 277171
pmc: PMC7737547
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2301-2311

Informations de copyright

© 2020 Macek et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in the present study.

Références

Metabolism. 2019 Mar;92:61-70
pubmed: 30586573
Nutrients. 2016 Jun 16;8(6):
pubmed: 27322313
Am J Clin Nutr. 1999 Sep;70(3):405-11
pubmed: 10479203
J Nutr. 2011 Aug;141(8):1573-80
pubmed: 21715469
Nat Rev Endocrinol. 2020 Mar;16(3):177-189
pubmed: 32020062
PLoS One. 2012;7(1):e29580
pubmed: 22253741
Am J Clin Nutr. 2014 Apr;99(4):875-90
pubmed: 24452240
Circulation. 1999 Sep 28;100(13):1481-92
pubmed: 10500053
Diabetes Metab Res Rev. 2019 May;35(4):e3135
pubmed: 30715772
Exp Gerontol. 2020 Jul 1;135:110937
pubmed: 32240820
Ageing Res Rev. 2012 Jul;11(3):361-73
pubmed: 22440321
Nutr Diabetes. 2018 Jul 19;8(1):43
pubmed: 30026463
Obes Res. 1995 Sep;3(5):435-46
pubmed: 8521163
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
Diabetes Metab Syndr Obes. 2018 Jun 01;11:241-253
pubmed: 29910627
Int J Obes (Lond). 2008 Aug;32 Suppl 3:S56-9
pubmed: 18695655
Obes Res. 2005 Nov;13(11):1849-63
pubmed: 16339115
Am J Clin Nutr. 2007 Jul;86(1):82-91
pubmed: 17616766
Obes Facts. 2017;10(3):216-222
pubmed: 28564658
Br J Nutr. 2008 May;99(5):931-40
pubmed: 17977473
Biol Sex Differ. 2018 Jun 27;9(1):28
pubmed: 29950175
Diabetes Care. 2012 Feb;35(2):383-8
pubmed: 22179957
Am J Clin Nutr. 2007 Feb;85(2):405-10
pubmed: 17284736
Lancet Diabetes Endocrinol. 2014 Oct;2(10):819-29
pubmed: 24731660
Appl Physiol Nutr Metab. 2014 Jan;39(1):1-20
pubmed: 24383502
JAMA. 2012 Feb 1;307(5):491-7
pubmed: 22253363
Obes Facts. 2019;12(3):307-315
pubmed: 31132777
Br J Prev Soc Med. 1971 Feb;25(1):42-50
pubmed: 5551233
J Clin Med. 2020 Sep 08;9(9):
pubmed: 32911835
Am J Clin Nutr. 2012 Apr;95(4):989-94
pubmed: 22434603
PLoS One. 2015 May 27;10(5):e0127198
pubmed: 26018910
Clin Exp Pharmacol Physiol. 2015 Jan;42(1):1-13
pubmed: 25311629
Int J Environ Res Public Health. 2016 Aug 13;13(8):
pubmed: 27529269
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Soc Theory Health. 2018 Aug;16(3):256-271
pubmed: 31007613
Nutrition. 2004 Mar;20(3):255-60
pubmed: 14990265
J Appl Physiol (1985). 1997 Jul;83(1):229-39
pubmed: 9216968
J Clin Endocrinol Metab. 2004 Aug;89(8):3864-71
pubmed: 15292319
AJNR Am J Neuroradiol. 2005 Sep;26(8):2077-85
pubmed: 16155162
Eur J Clin Nutr. 2008 Dec;62(12):1440-8
pubmed: 17717537
Demography. 2009 Nov;46(4):851-72
pubmed: 20084832
Clin Interv Aging. 2020 Feb 05;15:161-169
pubmed: 32103918
Ann Agric Environ Med. 2019 Jun 17;26(2):341-349
pubmed: 31232069

Auteurs

Pawel Macek (P)

Institute of Health Sciences, Collegium Medicum, The Jan Kochanowski University, Kielce, Poland.
Department of Epidemiology and Cancer Control, Holycross Cancer Centre, Kielce, Poland.

Malgorzata Terek-Derszniak (M)

Department of Rehabilitation, Holycross Cancer Centre, Kielce, Poland.

Malgorzata Biskup (M)

Institute of Health Sciences, Collegium Medicum, The Jan Kochanowski University, Kielce, Poland.
Department of Rehabilitation, Holycross Cancer Centre, Kielce, Poland.

Halina Krol (H)

Institute of Health Sciences, Collegium Medicum, The Jan Kochanowski University, Kielce, Poland.
Research and Education Department, Holycross Cancer Centre, Kielce, Poland.

Jolanta Smok-Kalwat (J)

Clinical Oncology Clinic, Holycross Cancer Centre, Kielce, Poland.

Stanislaw Gozdz (S)

Institute of Health Sciences, Collegium Medicum, The Jan Kochanowski University, Kielce, Poland.
Clinical Oncology Clinic, Holycross Cancer Centre, Kielce, Poland.

Marek Zak (M)

Institute of Health Sciences, Collegium Medicum, The Jan Kochanowski University, Kielce, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH